Back to list
Drug discovery · Pharmacology and safety modelling

PBPK and pharmacokinetic modelling

Build research-use pharmacokinetic models from species physiology, compound properties and in-vitro or in-vivo data to compare exposure scenarios and parameter sensitivity.

Discuss your research question
Original scientific visual for PBPK and pharmacokinetic modelling
01
OVERVIEW

What PBPK and pharmacokinetic modelling is designed to address

PBPK and pharmacokinetic modelling is not a one-score software run. It is a reviewable analysis path organised around “Can available property and PK data support exposure-trend analysis across dosing scenarios?”, beginning with input quality, comparators and intended use of evidence before selecting an appropriate methodological level.

The work centres on Parameter curation and model-structure selection, PBPK or population-PK fitting, Sensitivity, identifiability and scenario simulation and links Physicochemical and ADME parameters, Dose and sampling times, Concentration data and species information directly to Model, parameters and fit diagnostics, Exposure curves and scenario comparisons, Uncertainty and data gaps. Reporting separates supporting evidence, conflicting signals, parameter dependence and conditions for follow-up validation.

Can available property and PK data support exposure-trend analysis across dosing scenarios?

Suitable research settings

  • Projects that need to answer “Can available property and PK data support exposure-trend analysis across dosing scenarios?”
  • Studies requiring consistent comparison and quality control across Parameter curation and model-structure selection and PBPK or population-PK fitting
  • Teams that need Model, parameters and fit diagnostics, Exposure curves and scenario comparisons, Uncertainty and data gaps with complete reproduction records
02
SERVICE SCOPE

Analyses included in the service

Parameter curation and model-structure selection

Apply Parameter curation and model-structure selection to physicochemical and adme parameters and produce model, parameters and fit diagnostics. First confirm that physicochemical and adme parameters can support the downstream analysis.

PBPK or population-PK fitting

Apply PBPK or population-PK fitting to dose and sampling times and produce exposure curves and scenario comparisons. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.

Sensitivity, identifiability and scenario simulation

Apply Sensitivity, identifiability and scenario simulation to concentration data and species information and produce uncertainty and data gaps. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.

03
METHOD SELECTION

Select the methodological level for the question

MethodBest suited toWatch for
Parameter curation and model-structure selectionEstablishing the input baseline and initial search space for PBPK and pharmacokinetic modellingErrors in PBPK and pharmacokinetic modelling input state, structure or data definition propagate through later steps
PBPK or population-PK fittingComparing candidate states, features or mechanisms in PBPK and pharmacokinetic modelling to form prioritiesPBPK and pharmacokinetic modelling comparisons require consistent conditions; raw scores are not experimental measurements
Sensitivity, identifiability and scenario simulationReviewing key PBPK and pharmacokinetic modelling results, interpreting differences and recording uncertaintyThis service supports research modelling and hypothesis assessment, not clinical dosing advice, regulatory conclusions or patient-level decisions.
04
WORKFLOW

From question definition to reproducible delivery

  1. Frame the research question

    Use “Can available property and PK data support exposure-trend analysis across dosing scenarios?” to define comparators, decision use, experimental context and the strength of evidence the computation can support.

  2. Review and curate inputs

    Review Physicochemical and ADME parameters, Dose and sampling times, Concentration data and species information; resolve structure, naming, unit, batch or microstate issues and record any remaining assumptions.

  3. Design methods and controls

    Combine Parameter curation and model-structure selection, PBPK or population-PK fitting, Sensitivity, identifiability and scenario simulation with controls, replicates, sensitivity checks or independent evidence, defining decision criteria before computation.

  4. Compute with quality control

    Run PBPK and pharmacokinetic modelling, including Parameter curation and model-structure selection, in a reproducible environment; retain inputs, versions, parameters, logs and intermediate outputs, and flag convergence, sampling, data-quality and applicability issues.

  5. Interpret and deliver

    Organise Model, parameters and fit diagnostics, Exposure curves and scenario comparisons, Uncertainty and data gaps while separating direct observations, model inference and working hypotheses, then prioritise experiments or follow-up computation.

05
INPUTS & DELIVERABLES

What is needed and what is delivered

Inputs

  • Physicochemical and ADME parameters
  • Dose and sampling times
  • Concentration data and species information

Optional supporting inputs

  • Known positive, negative or reference systems for basic expectation checks in PBPK and pharmacokinetic modelling
  • Replicate experiments, external databases or literature evidence relevant to PBPK and pharmacokinetic modelling
  • Timing, compute, software-compatibility or delivery-format constraints for PBPK and pharmacokinetic modelling

Deliverables

  • Model, parameters and fit diagnostics
  • Exposure curves and scenario comparisons
  • Uncertainty and data gaps
06
QUALITY CONTROL

Quality control and interpretation limits

How results are reviewed

  • PBPK and pharmacokinetic modelling: Standardise chemical structures, target states and assay context
  • PBPK and pharmacokinetic modelling: Review against known actives, decoys or simple baselines
  • PBPK and pharmacokinetic modelling: Record applicability domain, score agreement and uncertainty
  • PBPK and pharmacokinetic modelling: Check diversity, synthesizability and experimental testability

Boundaries that remain

  • This service supports research modelling and hypothesis assessment, not clinical dosing advice, regulatory conclusions or patient-level decisions.
  • PBPK and pharmacokinetic modelling results apply only to the recorded inputs, parameters, models and sampling scope. Changes to input state, comparison conditions or project objectives may require new computation.
07
PROJECT PATTERNS

Common ways projects begin

From one system to comparable candidates

When physicochemical and adme parameters are available but decision criteria are inconsistent, establish baselines and controls, then use Parameter curation and model-structure selection, PBPK or population-PK fitting, Sensitivity, identifiability and scenario simulation to build candidate tiers and deliver model, parameters and fit diagnostics with a difference analysis.

Independent review of existing results

When results relevant to PBPK and pharmacokinetic modelling conflict, revisit physicochemical and adme parameters and analytical assumptions around Parameter curation and model-structure selection, then add replicates, sensitivity checks or alternative models to distinguish signal from method conditions.

08
FAQ

Questions before a project begins

What is required before PBPK and pharmacokinetic modelling begins?

The minimum inputs are Physicochemical and ADME parameters, Dose and sampling times, Concentration data and species information. If information is incomplete, an input audit identifies which gaps change method selection and which can be handled as explicit assumptions.

Can the result directly prove “Can available property and PK data support exposure-trend analysis across dosing scenarios?”?

No single model output should be treated as experimental fact. This service supports research modelling and hypothesis assessment, not clinical dosing advice, regulatory conclusions or patient-level decisions. Quality controls determine whether results support a priority or mechanism hypothesis; key conclusions still require appropriate experiments or independent data.

Which reusable files are delivered?

Typical delivery includes Model, parameters and fit diagnostics, Exposure curves and scenario comparisons, Uncertainty and data gaps, together with input-curation records, key parameters, software and database versions, quality-control results, editable figures and limitations. Exact raw formats are confirmed in the project plan.

START WITH THE QUESTION

Describe your research question and we will evaluate the right computational path

Start a project